As survivin has already been shown to modulate the integrin proteins CD49d, CD11b, and CD11c on leukocytes (Mera et al, 2008), we hypothesised that it may also modulate the invasive capabilities of cancer cells. This evidence concerns the gene BIRC5 and cancer.